Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- A person must be willing and able to give their informed consent to participate.
- Male adults between 18 and 75 years of age may be eligible.
- People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma) that has been confirmed by laboratory testing, and whose cancer has a specific gene mutation related to DNA repair (such as BRCA1/2, ATM, CDK12, CHEK1/2, or several others detected by genetic sequencing).
- People whose prostate cancer has spread to other parts of the body and is no longer responding to hormone-lowering treatment (known as metastatic castration-resistant prostate cancer), and for whom a PARP inhibitor treatment is being considered by their doctor.
- People who have at least one measurable area of cancer visible on imaging scans.
- People who are able to provide a suitable tissue sample from their tumour (collected before any treatment began) that meets specific quality requirements.
- People with a general health status rated as fully active or restricted only in physically strenuous activity (confirm with trial site).
- People whose doctors estimate they have a life expectancy of at least 12 weeks.
Who may not be able to join:
- People who do not meet all of the inclusion criteria listed above.
- People who are currently receiving other cancer treatments such as chemotherapy or immunotherapy.
- People who have had an organ transplant within the past 3 months.
- People who have an autoimmune disease, or a history of hepatitis B, hepatitis C, or HIV infection.
- People who currently have pneumonia.
- People who have a serious ongoing illness or health condition that the trial doctors consider would make participation unsuitable.
- People who are unwilling or unable to give informed consent.
- People whom the trial investigators consider unsuitable for participation for any other reason.
- People who do not follow the trial's medication rules in a way that could affect the assessment of the treatment's effectiveness or safety may be removed from the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yonghong Li, M.D., Sun Yat-sen University
Phone: +020-87343656
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Radiological progression free survival (rPFS); Objective Response Rate (ORR); PSA response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.